Zafgen Inc. (NASDAQ:ZFGN)‘s stock had its “hold” rating restated by equities research analysts at FBR & Co in a research note issued to investors on Tuesday.

Other equities analysts also recently issued reports about the company. Cowen and Company reaffirmed a “buy” rating and issued a $60.00 price target on shares of Zafgen in a report on Thursday, August 25th. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Tuesday, July 26th. Canaccord Genuity set a $4.00 price objective on Zafgen and gave the company a “hold” rating in a report on Thursday, July 21st. Finally, Leerink Swann reissued a “market perform” rating and issued a $6.00 price objective on shares of Zafgen in a report on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zafgen currently has an average rating of “Hold” and a consensus price target of $14.22.

Shares of Zafgen (NASDAQ:ZFGN) opened at 3.26 on Tuesday. The company has a 50-day moving average of $3.13 and a 200-day moving average of $5.40. Zafgen has a 1-year low of $2.90 and a 1-year high of $42.89. The firm’s market cap is $89.09 million.

In related news, CFO Patricia L. Allen purchased 16,000 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was acquired at an average price of $3.12 per share, for a total transaction of $49,920.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas E. Hughes purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were bought at an average price of $3.00 per share, with a total value of $30,000.00. Following the purchase, the insider now directly owns 63,936 shares of the company’s stock, valued at $191,808. The disclosure for this purchase can be found here. Insiders own 20.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. acquired a new position in Zafgen during the second quarter valued at about $114,000. Bellevue Group AG acquired a new position in Zafgen during the first quarter valued at about $134,000. ProShare Advisors LLC boosted its position in Zafgen by 4.9% in the second quarter. ProShare Advisors LLC now owns 23,099 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 1,075 shares during the last quarter. Rhumbline Advisers boosted its position in Zafgen by 103.0% in the second quarter. Rhumbline Advisers now owns 34,692 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 17,602 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in Zafgen by 25.1% in the second quarter. Alps Advisors Inc. now owns 38,312 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 7,683 shares during the last quarter. Institutional investors and hedge funds own 62.83% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

5 Day Chart for NASDAQ:ZFGN

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.